🎉 New Year, New Paper! We're excited to share our latest study led by @kyletreid.bsky.social, demonstrating human IL-10-producing ILC2s can be harnessed in cell therapies. 🧬✨ www.cell.com/cell-reports...
#Immunology #Transplantation #GVHD #RegenerativeMedicine #CellTherapy #ILC2
www.cell.com
Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses
Reid et al. report that IL-10⁺ ILC2 cell therapy inhibits graft-versus-host disease (GVHD) in humanized mice, consistent with patient studies where IL-10⁺ ILC2s are associated with protection from GVHD. Human IL-10⁺ ILC2s express CD49d and CD86 and inhibit allogeneic T cell responses via an IL-4- and IL-10-dependent mechanism. These findings support harnessing IL-10⁺ ILC2s therapeutically.
3 11 54
